Get the Stockscreener App
6.09
5.58%
-0.36
After Hours:
6.09
Evolus Inc stock is traded at $6.09, with a volume of 627.50K.
It is down -5.58% in the last 24 hours and up +17.34% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$6.45
Open:
$6.5
24h Volume:
627.50K
Relative Volume:
0.58
Market Cap:
$401.06M
Revenue:
$301.79M
Net Income/Loss:
$-43.42M
P/E Ratio:
-9.0828
EPS:
-0.6705
Net Cash Flow:
$-44.87M
1W Performance:
-6.31%
1M Performance:
+17.34%
6M Performance:
-11.09%
1Y Performance:
-36.30%
1-Day Range:
$6.075
$6.50
1-Week Range:
$6.075
$6.765
52-Week Range:
$3.86
$10.62
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.09 | 424.76M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga
Evolus Q1 2026 earnings preview - MSN
Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus
Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK
Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal
Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com
Evolus launches Estyme in Europe with commercial debut targeted for May 16 - Traders Union
Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe - TradingView
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - ChartMill
What is HC Wainwright's Estimate for Evolus Q2 Earnings? - MarketBeat
Evolus Plans to Launch Estyme Collection in Europe - Moomoo
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy - Investing.com Australia
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy By Investing.com - Investing.com South Africa
Evolus | 4: Statement of changes in beneficial ownership of securities-Officer MOATAZEDI DAVID - Moomoo
Evolus, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-05-07 - Seeking Alpha
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin - MSN
Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com
Evolus Earnings Call Highlights Profitable Growth Path - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps - TipRanks
PREVIEW-Weight-loss revolution sparks new appetite for aesthetics firms - Sahm
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $13 to $17 - Moomoo
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript - Insider Monkey
Evolus, Inc. 2026 Q1 Financial Report: Key Risks, Financials, and Business Updates - Minichart
Earnings call transcript: Evolus misses Q1 2026 EPS forecast, revenue up - Investing.com UK
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Evolus Sees 2026 Rev $327M-$337M >EOLS - Moomoo
Is Evolus (EOLS) Finally Turning the Corner on Profitability? - Kavout
Evolus Q1 2026 Earnings Call Transcript - MarketBeat
Evolus | 8-K: Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - Moomoo
Evolus, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Evolus | 10-Q: Q1 2026 Earnings Report - Moomoo
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally - ChartMill
Evolus Q1 Earnings Call Highlights - Yahoo Finance
Evolus Shares up After Q1 Revenue Tops Consensus - Orange County Business Journal
Earnings call transcript: Evolus misses Q1 2026 EPS forecast, revenue up By Investing.com - Investing.com South Africa
Evolus (EOLS) Q1 2026 Earnings Transcript - AOL.com
EOLS Reports Strong Q1 Revenue and Positive Adjusted EBITDA - GuruFocus
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary - TradingView
Evolus (NASDAQ: EOLS) grows Q1 2026 sales but remains unprofitable - Stock Titan
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):